News
Pharmalittle: We’re reading about an FDA rejection, the Big Beautiful Bill’s cost, and much more
The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...
The FDA will soon require prescription opioid manufacturers to include stronger language on the medications’ label warning ...
The FDA's top regulator of cancer drugs played a key role in the rejection of a skin cancer therapy from Replimune Group, ...
Why pharma companies' "price transparency" reports paint a murky picture of how much Americans spend on prescription drugs.
Many San Diego biotech firms are struggling to raise money, with the uncertainty exacerbated by the Trump administration’s ...
The prelude to a transplant. A pause before a treatment plan can proceed. For every person in it, the waiting demands a balance between holding on and letting go.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback